This suggests that MAGL is a key modulator of gut microbiota composition, inflammation and amyloidosis and might be considered as a potential next-generation target whose deep investigation might provide new therapeutic strategy against AD etiology and its modifiable risk factors. The gene discussed is MGLL; the disease is Alzheimer disease.